Drug Type Small molecule drug |
Synonyms VU0364852 |
Target |
Action inhibitors |
Mechanism ALK2 inhibitors(Activin receptor type-1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anemia | Preclinical | United States | 02 Jun 2013 | |
Atherosclerosis | Preclinical | United States | 02 Jun 2013 | |
Muscular Dystrophy, Duchenne | Preclinical | United States | 02 Jun 2013 | |
Myositis Ossificans | Preclinical | United States | 02 Jun 2013 | |
Ossification, Heterotopic | Preclinical | United States | 02 Jun 2013 |